Brief: European Commission approves Guerbet's half-dose GBCA, Elucirem for newborns and children
27/01/2026 17:06
Jan 27 (Reuters) - Guerbet SA GRBT.PA: NEW INDICATION IN CHILDREN FROM BIRTH FOR GUERBET'S HALF-DOSE GBCA, ELUCIREM™ (GADOPICLENOL) APPROVED BY EUROPEAN COMMISSION Source text: ID:nPremYxm5a Further company coverage: GRBT.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48587696600;;))
Recent news on Guerbet SA
See all newsBrief: Guerbet Q1 Revenue At EUR 177.4 Mln
Guerbet Q1 revenue up 2.6% at CER on increased volumes in EMEA and Asia
Medical imaging firm Guerbet's 2025 revenue falls on lower sales activity in France
Brief: Guerbet Says FDA Approves Labeling Update For Guerbet's Elucirem Injection
France's Guerbet misses 2025 revenue estimates